search button

DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study

  • Authors:
    • Zeng‑Li Feng
    • Liu‑Bin Chen
    • Zhen‑Yu Liu
    • Xue‑Ji Chen
    • Xiao‑Can Ren
    • Yue‑E Liu
    • Yu Peng
    • Hai‑Gang Wang
    • Shun‑Mao Ma
    • Feng‑Jie Meng
    • Qiang Lin

  • View Affiliations

  • Published online on: October 31, 2014     https://doi.org/10.3892/ol.2014.2651
  • Pages: 491-497
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is the fourth most common type of cancer globally and accounts for the second highest cancer‑associated mortality rate in the world. Current treatment strategies for gastric cancer include surgery, radiotherapy, chemotherapy and targeted therapy. Intraperitoneal (IP) chemotherapy may increase the IP concentrations of chemotherapy drugs and reduce the systemic toxicity. At present, IP chemotherapy is used to treat patients with advanced gastric cancer, which has a high rate of peritoneal recurrence. The present study evaluated the feasibility of using docetaxel, cisplatin and fluorouracil (DCF) in an IP and intravenous (IV) dual chemotherapy regimen for the treatment of advanced gastric cancer. The treatment‑associated adverse reactions and preliminary efficacy were reported. The first dose level utilized the full dose of DCF: Docetaxel, day one, 45 mg/m2 (IP) and day eight, 30 mg/m2 (IV); cisplatin (DDP), day one, 75 mg/m2 (IP); and fluorouracil (FU), days one to five, 750 mg/m2 (continuous IV). A total of six patients were treated at this level and two patients withdrew due to serious adverse reactions. Taking into account that the the tolerated doses used in combination regimens for Eastern populations are lower than that of the corresponding doses for Western populations, the dosages of the three drugs were all reduced by 20% in the application of the second dose level: Docetaxel, day one, 30 mg/m2 (IP) and day eight, 30 mg/m2 (IV); DDP, day two, 60 mg/m2 (IP); and FU, days one to five, 600 mg/m2 (continuous IV). A total of 26 patients were treated at this level. The main adverse reaction was bone marrow suppression, with grade III/IV neutropenia, leukopenia and febrile neutropenia accounting for 61.5, 53.8 and 19.2% of reactions, respectively, and grade III/IV anemia and thrombocytopenia accounting for 19.2 and 15.4% of reactions, respectively. Gastrointestinal adverse reactions primarily consisted of abdominal pain, with grade III/IV abdominal pain accounting for 30.8% of reactions. Only 7.7% of the patients withdrew from the treatment. The median time to progression (TTP) was five months [95% confidence interval (CI), 1.0‑9.0 months], and the median overall survival (OS) was nine months (95% CI, 7.4‑10.6 months). It was concluded that the DCF regimen with reduced dosage should be applied. IP and IV dual chemotherapy for the treatment of unresectable advanced gastric cancer is tolerated and demonstrated a good initial efficacy. Strategies for mitigating and reducing the adverse gastrointestinal reactions, particularly abdominal pain, may be the focus of future studies.
View Figures
View References

Related Articles

Journal Cover

January-2015
Volume 9 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Feng ZL, Chen LB, Liu ZY, Chen XJ, Ren XC, Liu YE, Peng Y, Wang HG, Ma SM, Meng FJ, Meng FJ, et al: DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study. Oncol Lett 9: 491-497, 2015.
APA
Feng, Z., Chen, L., Liu, Z., Chen, X., Ren, X., Liu, Y. ... Lin, Q. (2015). DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study. Oncology Letters, 9, 491-497. https://doi.org/10.3892/ol.2014.2651
MLA
Feng, Z., Chen, L., Liu, Z., Chen, X., Ren, X., Liu, Y., Peng, Y., Wang, H., Ma, S., Meng, F., Lin, Q."DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study". Oncology Letters 9.1 (2015): 491-497.
Chicago
Feng, Z., Chen, L., Liu, Z., Chen, X., Ren, X., Liu, Y., Peng, Y., Wang, H., Ma, S., Meng, F., Lin, Q."DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study". Oncology Letters 9, no. 1 (2015): 491-497. https://doi.org/10.3892/ol.2014.2651